Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04515550 · ClinicalTrials.gov registry record
Mitochondrial Biomarkers in Huntington's Disease
A clinical trial of Huntington Disease, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- 27
- Enrollment target
- 1
- Study location
NCT04515550: Completed study of Huntington Disease, sponsored by University Hospitals Cleveland Medical Center.
NCT04515550 is a study of Huntington Disease that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 27 participants, below the 635-participant average among 35 other Huntington Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04515550, a study of Huntington Disease, has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to discover a panel of mitochondrial metabolomics biomarkers for Huntington's disease.
Primary Outcome
This is a questionnaire and neurological examination. Lower values are better than higher values.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST lumbar puncture
Study Locations (1)
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2019-04-04 |
| Est. Completion | 2022-02-28 |
What the finished NCT04515550 record still lists
NCT04515550 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 635-participant average among 35 other Huntington Disease trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 1 intervention - of which lumbar puncture is the first listed.
NCT04515550 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04515550 about?
NCT04515550 is a clinical study titled "Mitochondrial Biomarkers in Huntington's Disease". The objective of this study is to discover a panel of mitochondrial metabolomics biomarkers for Huntington's disease.
What is the current status of trial NCT04515550?
This trial is currently completed. The enrollment target is 27 participants. The study started on 2019-04-04. Estimated completion is 2022-02-28.
What conditions does trial NCT04515550 study?
This clinical trial studies the following conditions: Huntington Disease.
What interventions are being tested in trial NCT04515550?
The interventions under investigation include: lumbar puncture (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04515550?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04515550 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04515550's enrollment target sits among peer trials
27 27th of 35 higher than 9 of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Longitudinal Endpoint Assessment of Disease Burden in HD
RECRUITING
-
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
RECRUITING
-
Extracellular Vesicles for HD
RECRUITING
-
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
RECRUITING · Phase 3
-
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI